These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36518189)

  • 1. Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen-Bethesda assay.
    Ketteler C; Hoffmann I; Davidson S; Chen D; Tiede A; Richter N
    Res Pract Thromb Haemost; 2022 Nov; 6(8):e12799. PubMed ID: 36518189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].
    Feng HM; Li Q; Xu WS; Chen DM; Zheng L
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):592-5. PubMed ID: 27113194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].
    Fan LK; Wang ZW; Hua BL; Su W; Wang SJ; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):551-4. PubMed ID: 19968068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU/mL.
    Verbruggen B; Binder NB; van Velp PJC; Polenewen R; Knöbl P; Sobas F; Moore GW
    J Thromb Haemost; 2024 Oct; 22(10):2745-2751. PubMed ID: 38992344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
    Kershaw GW; Chen LS; Jayakodi D; Dunkley SM
    Thromb Res; 2013; 132(6):735-41. PubMed ID: 24119613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.
    Miller CH; Boylan B; Shapiro AD; Lentz SR; Wicklund BM;
    J Thromb Haemost; 2017 Oct; 15(10):1971-1976. PubMed ID: 28795528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A.
    Valke LLFG; Verhagen MJA; Mulders BTPM; Polenewen R; Blijlevens NMA; Jansen JH; Mansouritorghabeh H; Elsheikh E; Reipert BM; Turecek PL; O'Donnell JS; Rijpma SR; Schols SEM; van Heerde WL; Meijer D
    Thromb Res; 2023 Nov; 231():112-120. PubMed ID: 37844518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A.
    Oomen I; Verhagen M; Miranda M; Allacher P; Beckers EAM; Blijlevens NMA; van der Bom JG; Coppens M; Driessens M; Eikenboom JCJ; Fijnvandraat K; Hassan S; van Heerde WL; Hooimeijer HL; Jansen JH; Kaijen P; Leebeek FWG; Meijer D; Paul H; Rijpma SR; Rosendaal FR; Smit C; van Vulpen LFD; Voorberg J; Schols SEM; Gouw SC
    Front Immunol; 2024; 15():1355813. PubMed ID: 38455035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors.
    Négrier C; Oldenburg J; Kenet G; Meeks SL; Bordet JC; Müller J; Le Quellec S; Turecek PL; Tripkovic N; Dargaud Y
    Res Pract Thromb Haemost; 2022 May; 6(4):e12731. PubMed ID: 35765670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time-based clotting time test results in patients treated with emicizumab.
    Novembrino C; Boscolo-Anzoletti M; Galbiati E; Shinohara S; Peyvandi F
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102260. PubMed ID: 38193066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.
    Miller CH; Rice AS; Boylan B; Shapiro AD; Lentz SR; Wicklund BM; Kelly FM; Soucie JM;
    J Thromb Haemost; 2013 Jul; 11(7):1300-9. PubMed ID: 23601690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A variation of the Nijmegen-Bethesda assay using heat or a novel heat/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity.
    Millner AH; Tiefenbacher S; Robinson M; Boesen HT
    Int J Lab Hematol; 2016 Dec; 38(6):639-647. PubMed ID: 27545696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nijmegen-Bethesda assay to measure factor VIII inhibitors.
    Duncan E; Collecutt M; Street A
    Methods Mol Biol; 2013; 992():321-33. PubMed ID: 23546724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.
    Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF
    Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.
    Eubanks J; Baldwin WH; Markovitz R; Parker ET; Cox C; Kempton CL; Meeks SL
    Blood; 2016 Apr; 127(16):2028-34. PubMed ID: 26825708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII.
    Barrow RT; Lollar P
    J Thromb Haemost; 2006 Oct; 4(10):2223-9. PubMed ID: 16856973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
    Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
    J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.